Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 2.3% Higher

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRXGet Free Report) rose 2.3% on Monday . The stock traded as high as $7.56 and last traded at $7.49. Approximately 792,935 shares traded hands during trading, a decline of 87% from the average daily volume of 6,186,341 shares. The stock had previously closed at $7.32.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC restated a “buy” rating and set a $17.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, June 25th.

Check Out Our Latest Stock Report on Recursion Pharmaceuticals

Recursion Pharmaceuticals Stock Performance

The firm has a market cap of $1.72 billion, a PE ratio of -4.52 and a beta of 0.83. The firm has a fifty day simple moving average of $8.77 and a two-hundred day simple moving average of $9.83.

Recursion Pharmaceuticals (NASDAQ:RXRXGet Free Report) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.04. The business had revenue of $13.80 million during the quarter, compared to analysts’ expectations of $11.10 million. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The firm’s revenue for the quarter was up 14.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.34) EPS. Equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current fiscal year.

Insider Activity

In other news, CEO Christopher Gibson sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total value of $386,500.00. Following the completion of the sale, the chief executive officer now directly owns 863,524 shares of the company’s stock, valued at approximately $6,675,040.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $7.66, for a total transaction of $87,684.02. Following the completion of the sale, the director now directly owns 7,229,861 shares of the company’s stock, valued at approximately $55,380,735.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Christopher Gibson sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total value of $386,500.00. Following the sale, the chief executive officer now directly owns 863,524 shares of the company’s stock, valued at $6,675,040.52. The disclosure for this sale can be found here. Insiders sold 207,359 shares of company stock valued at $1,704,435 in the last ninety days. Insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Benjamin F. Edwards & Company Inc. bought a new stake in shares of Recursion Pharmaceuticals during the 1st quarter worth approximately $26,000. National Bank of Canada FI lifted its stake in shares of Recursion Pharmaceuticals by 90.9% during the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after acquiring an additional 1,500 shares during the last quarter. First Horizon Advisors Inc. bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter worth approximately $47,000. GAMMA Investing LLC lifted its stake in shares of Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after acquiring an additional 6,036 shares during the last quarter. Finally, Oxford Wealth Group LLC bought a new stake in shares of Recursion Pharmaceuticals during the 1st quarter worth approximately $106,000. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Company Profile

(Get Free Report)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

Further Reading

Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.